Mediarka Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 09-12-2024
- Paid Up Capital ₹ 0.50 M
as on 09-12-2024
- Company Age 9 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.75 M
as on 09-12-2024
About Mediarka Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹5.75 M.
Nilay Saini and Meenu Saini serve as directors at the Company.
- CIN/LLPIN
U24232CH2015PTC035461
- Company No.
035461
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Mar 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Mediarka Lifesciences Private Limited offer?
Mediarka Lifesciences Private Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, PCD Pharma Franchise, Marketing Services & Consultants, Marketing Services, Pain Relief Drugs & Pharmaceuticals, Diclofenac, Nutraceuticals & Dietary Supplements, Vitamin & Multivitamin Injections, Pharmaceutical Third Party Manufacturing, Anti Infective Drugs & Medicines.
Who are the key members and board of directors at Mediarka Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nilay Saini  | Director | 18-Mar-2015 | Current |
| Meenu Saini | Director | 18-Mar-2015 | Current |
Financial Performance of Mediarka Lifesciences.
Mediarka Lifesciences Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Mediarka Lifesciences?
Unlock access to Mediarka Lifesciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 10 Nov 2021 | ₹0.25 M | Open |
Canara Bank Creation Date: 25 Jun 2020 | ₹0.50 M | Open |
Canara Bank Creation Date: 07 Sep 2017 | ₹5.00 M | Open |
How Many Employees Work at Mediarka Lifesciences?
Unlock and access historical data on people associated with Mediarka Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mediarka Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mediarka Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
